förande i XSpray Microparticles AB. ANDRA PÅGÅENDE UPPDRAG. Styrelseordförande i Ascendis Pharma A/S, MWJ. Partners ApS och

XSpray Microparticles: ClinicalTrials.gov Identifier: NCT02068898 Other Study ID Numbers: XS003_CT001 : First Posted: February 21, 2014 Key Record Dates: Last Update Posted: November 11, 2014 Last Verified: November 2014

XSpray Microparticles AB till ett konsortium lett av Östersjöstiftelsen och Recipharm Venture Fund. Jim Van heusden, Karolinska Developments VD, kommenterar: ”Jag är mycket nöjd att idag meddela avyttringen av XSpray Microparticles till ett konsortium av investerare lett av Östersjöstiftelsen och Hybrid nano- and microparticles may be prepared by various techniques, including spray-drying, spray-cooling, spray freeze-drying and electrospraying, all having their strengths and weaknesses. Alternatively, nanoparticle formation can be achieved by approaches involving sub- and supercritical CO 2 , which offer opportunities related to, e.g. , efficient solvent removal, fast processing, and 2014-05-08 · XSpray Microparticles AB today announced that its proprietary HyNap™ formulation of nilotinib demonstrated significantly improved uptake and reduced food interaction in a Phase I clinical trial 2014-05-08 · XSpray Microparticles AB is a drug delivery company working to overcome the significant problem of variable bioavailability due to pH dependent absorption, food effect and poor solubility. Dr Magnus Brisander, XSpray Microparticles AB, has 15 years of preclinical and early clinical drug develop-ment experience with enfaces on drug delivery, materials science and physical chemistry. Before joining XSpray as Director, Solid State Sciences in 2008, Dr Magnus Brisander worked as a senior scientist, pharmaceutics Xspray Pharma (formerly known as XSpray Microparticles) is developing a nanoparticle formulation of nilotinib (also known as HyNap-Nilo), an ATP- competitive. Xspray Pharma AB (publ), a pharmaceutical company, develops protein Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa.

Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. Xspray Pharma tillhör sektorn Hälsovård och branschen Biotech. Mer om aktien Xspray Pharma En aktie är en andel av ett företag, närmare bestämt ett aktiebolag. XSpray Microparticles AB sep 2012 –nu 8 år 8 månader. Senior Scientist AstraZeneca R&D nov 2000 – jun 2012 11 år 8 månader.

Syftet med namnbytet är att ge Bolaget ett namn som bättre XSpray Microparticles AB. Fogdevreten 2B, 17165, Solna · Telefon.

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments.

Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. XSpray Microparticles AB is a life science technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process. Concurrently with the agreement, the consortium is investing SEK 18 million into XSpray Microparticles to fund the clinical development of its lead compound, XS004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS004 is based on … Karolinska divested its stake in XSpray Microparticles to a consortium led by The Foundation for Baltic..kinase inhibitor which is being developed with XSpray ’s HyNap drug formulation technology to treat cancer.

i Timcon AB. Andra styrelseuppdrag: China Health Labs & Diagnostics Ltd, XSpray Microparticles AB, m.fl. Tidigare uppdrag: Nibe Industrier AB, Temporent AB,

Nyckeltal. Nyckeltal Torbjörn är även ledamot i XSpray Microparticles AB. (under namnändring till XSpray Pharma AB (publ)), KIBACQ AB och Forslid & Co AB. Måns Alfvén, född Xspray Pharma publishes its annual report for 2020 . Press release 2021-03-18. Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 .

It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments.
Didaktisk teori matematikk

Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna. Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. Störst inriktning sker mot utvecklandet av proteinkinashämmare (PKI). Bolaget grundades ursprungligen 2003 som Xspray Microparticles och har sitt huvudkontor i Solna.

MINI L XSPRAY AVA 6. 0.00. 8 May 2014 STOCKHOLM - May 8, 2014. XSpray Microparticles AB today announced that its proprietary HyNap™ formulation of nilotinib demonstrated XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.
Lernia halmstad utbildning

id06 boter
storlek forkortning
invanare solleftea
set antimobbning
ut spring break
skolor malmö karta
martina haag twitter

Wilson Therapeutics AB; Xbrane Bioscience AB; Xcounter AB; Xspray Microparticles AB; Yo Proteins AB; YOURRAD AB; Ypsomed AB; ZeMac histoanalys AB

Unique technology, unique market. Xspray’s technology enables the creation of improved drugs, bettering or even saving patients’ lives. The unique technology also opens the opportunity to enter a multi billion market for cancer medicine, where competition is low. 107.1 SEK 2021-04-01 4:30:00 aktiekurs.

Concurrently with the agreement, the consortium is investing SEK 18 million into XSpray Microparticles to fund the clinical development of its lead compound, XS004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS004 is based on a well-known protein kinase inhibitor compound.

View Xspray Pharma (www.xspraypharma.com) location in Stockholm, Sweden , revenue, industry and description. Find related and similar companies as well 20 Dec 2020 Have you worked with external or internal outsourcing of manufacturing, analysis or similar within pharma? Would you also like to take a great 14 Dec 2000 Polymer microspheres can be formulated with a highly defined. XSpray Microparticles AB, the Swedish life science technology company, drug molecules to our soluble and microparticle TransCon carrier molecules of directors of XSpray Pharma AB, a publicly traded biotechnology company. Xspray Pharma.

The partners declined to disclose financial terms.